KARD NASDAQ
Kardigan, Inc.
1W: -8.4%
1M: -11.1%
YTD: -4.6%
$20.99
-0.24 (-1.13%)
Weekly Expected Move ±11.5%
$16
$18
$21
$23
$25
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range16.25-27
Volume142,294
Avg Volume702,876
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOTassos Gianakakos
Employees241
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-18
Websitekardigan.bio
506 Carnegie Center Drive
Princeton, NJ 08540
US
Princeton, NJ 08540
US
(415) 573-3220
About Kardigan, Inc.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its âCardiac Intelligenceâ platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Latest News
Catalyst Watch: Bank earnings, Netflix results, Alzheimer's conference
Kardigan (KARD) Stock Price At $22 Raises Fresh Valuation Questions
Kardigan (KARD) Stock Price At $22 Raises Fresh Valuation Questions - Yahoo Finance
SA Asks: What are the most attractive upcoming IPOs?
KARD Price Today: Kardigan, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS | A-Award | 20,706 | — | 2026-06-17 |